Shearman & Sterling and Davis Polk & Wardwell have the lead roles on Indian generic drug maker Sun Pharmaceutical Industries Ltd.’s $3.2 billion acquisition of local competitor Ranbaxy Laboratories Ltd. from Japanese pharmaceutical company Daiichi Sankyo Co.
The deal, subject to Indian regulatory approval, will create world’s fifth-largest generic drug maker, with revenue of over $4.2 billion per year.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
